Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
RESEARCH TOOLSreports
Holding AU:ILA?
Track your performance easily
ILA Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.05 - AU$0.20
Previous CloseAU$0.17
Volume82.47K
Average Volume (3M)382.96K
Market Cap
AU$25.73M
Enterprise ValueAU$20.94M
Total Cash (Recent Filing)AU$4.79M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares OutstandingN/A
10 Day Avg. Volume300,596
30 Day Avg. Volume382,956
Standard Deviation0.21
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Island Pharmaceuticals Ltd News
PremiumCompany Announcements
Island Pharmaceuticals Secures R&D Tax Refund Boost
PremiumCompany Announcements
Island Pharmaceuticals Appoints New Director with Share Interests
PremiumCompany Announcements
Island Pharmaceuticals Announces Director ChangePremiumCompany Announcements
Island Pharmaceuticals to Quote New Shares on ASX
PremiumCompany Announcements
Island Pharmaceuticals Discusses AGM and Antiviral Progress
PremiumCompany Announcements
Island Pharmaceuticals Approves Key Resolutions at AGMPremiumCompany Announcements
Island Pharmaceuticals Advances Dengue Clinical TrialPremiumCompany Announcements
Island Pharmaceuticals Engages Investors in Exciting Drug TrialsOptions Prices
Currently, No data available
---
Ownership Overview
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.05 and its highest was AU$0.20 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Currently, no data Available
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Feb 20, 2025 which is in 89 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Aug 29, 2024. The company reported -AU$0.018 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.018.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 155,920,720 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.018 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
---
Island Pharmaceuticals Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.02%
12-Months-Change
Fundamentals
Return on Equity
-173.37%
Trailing 12-Months
Asset Growth
25.14%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its lead asset ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases.
---
Technical Analysis
---